- Article
Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure
- Harald Hefter,
- Beyza Ürer,
- Raphaela Brauns,
- Dietmar Rosenthal,
- Sven G. Meuth,
- John-Ih Lee,
- Philipp Albrecht and
- Sara Samadzadeh
Under continuous long-term treatment with abo- or onabotulinum toxin type A (BoNT/A), ~10 to 15% of patients with cervical dystonia (CD) will develop neutralizing antibodies and reduced responsiveness over an ~10-year treatment period. Among the botu...

